NEW YORK (GenomeWeb News) – Roche today announced that it has teamed with the Innovative Medicines Initiative to lead a consortium of industry and academic partners that will use stem cells for drug discovery research.

The project, called StemBANCC, will be initiated and coordinated by Roche, managed by Oxford University, and include 10 pharmaceutical companies and 23 academic institutions. Researchers involved in the effort will use human induced pluripotent stem cells as tools for drug discovery with the goal of developing human disease models and enhancing drug development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.